Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ — GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.